Evaluation of the Association of IGF2BP2 Variants with Type 2 Diabetes in French Caucasians
- Konsta Duesing1,
- Ghazaleh Fatemifar1,
- Guillaume Charpentier2,
- Michel Marre3,,4,
- Jean Tichet5,
- Serge Hercberg6,
- Beverley Balkau7,,8,
- Philippe Froguel1,,9 and
- Fernando Gibson (fernando.gibson{at}imperial.ac.uk)1
- 1Genomic Medicine, Imperial College London, Hammersmith Campus, Du Cane Rd, London W12 0NN, UK
- 2Endocrinology-Diabetology Unit, Corbeil Hospital, Corbeil, France
- 3Endocrinology-Diabetology, Bichat Hospital, Paris, France
- 4INSERM U695, Paris, France
- 5Institut Régional Pour la Santé, Tours, France
- 6U557 Inserm/U1125 Inra/Cnam/University Paris 13, CRNH IdF, F-93017 Bobigny, France
- 7INSERM U780-IFR69, Villejuif, France
- 8Paris Univ-Sud, Orsay, France
- 9CNRS 8090, Institut de Biologie de Lille, Institut Pasteur, CHU Lille, France
Abstract
Objective: We performed a comprehensive genetic association study of common variation spanning the IGF2BP2 locus, in order to replicate the association of the ‘confirmed’ type 2 diabetes susceptibility variants rs4402960 and rs1470579 in the French Caucasian population, and to further characterise the susceptibility variants at this novel locus.
Research Design and Methods: We genotyped a total of 21 tagging SNPs spanning the IGF2BP2 locus in our type 2 diabetes case-control cohort comprising in 3,093 French Caucasian subjects.
Results: IGF2BP2 variants rs4402960 and rs1470579 were not associated with type 2 diabetes in the present study (P = 0.632 and P = 0.896, respectively). Meta-analysis of genotype data from over 34,000 subjects demonstrated that our inability to replicate rs4402960/rs1470579 was consistent with the findings from several previous GWAS datasets that were under-powered to detect this modest association signal (OR 1.14). We obtained novel evidence that rs9826022, a borderline rare variant (5% MAF) in the 3′ downstream region, was associated with type 2 diabetes (P = 0.0002; OR 1.53 [95% CI 1.22-1.91]). This result was corroborated by the meta-analysis of 10,542 genotypes from the current study and GWAS datasets using both fixed (P = 9.47 × 10−6; OR 1.30 [95% CI 1.16-1.46]) and random effects (P = 0.001; 1.30 [95 %CI 1.11-1.52)] calculations.
Conclusions: We were unable to replicate the confirmed rs4402960/rs1470579 susceptibility variants, but found novel evidence for a rare variant in the 3′ downstream region of IGF2BP2. Further genetic and functional studies are required to identify the aetiological IGF2BP2 variants.
Footnotes
-
- Received December 17, 2007.
- Accepted April 17, 2008.
- Copyright © American Diabetes Association











